Few studies evaluated patient-reported outcomes (PROs) for patients with hematologic
malignancies receiving with Chimeric Antigen Receptor T (CAR-T) cell therapy. We …

The inclusion of patient-reported outcome (PRO) measures in chimeric antigen receptor
(CAR) T-cell therapy research is critical for understanding the impact of this novel approach …

Importance Multicomponent electronic patient-reported outcome cancer symptom
management systems reduce symptom burden. Whether all components contribute to …

Simple Summary In clinical trials, patients treated with idecabtagene vicleucel (ide-cel)
chimeric antigen receptor T-cell therapy (CAR T) have reported meaningful improvements in …

The approval of tisagenlecleucel (tisa-cel) for use in children with B cell acute lymphoblastic
leukemia (B-ALL) was based on the phase 2 ELIANA trial, a global registration study …

Purpose The experiences of patients with diffuse large B-cell lymphoma (DLBCL) treated
with chimeric antigen receptor (CAR) T-cell therapy have received little attention. This study …

Chimeric antigen receptor (CAR) T-cell therapy has transformed the care of patients with
relapsed/refractory B-cell-derived hematologic malignancies. To date, six CAR T-cell …

Chimeric antigen receptor (CAR) T-cell therapy is associated with potentially severe
toxicities that create a substantial burden for patients. Patient-reported outcomes (PROs) …

Background The advancement of information and communication technologies has spurred
a growing interest in and increased applications of patient-generated health data (PGHD). In …

Abstract Immune Effector Cell (IEC) therapy represents a transformative advancement in
oncology, leveraging the immune system to combat various malignancies. This manuscript …